American Diversified Holdings Corporation (ADHC) Provides Udpate on Arete Bioscience GlucoGuard Design Project

Core Insights - American Diversified Holdings Corporation (ADHC) announces significant progress by its bioengineering firm Arete Biosciences in various development areas [1] Company Overview - Arete Biosciences specializes in the design and development of early-stage medical technologies, leveraging a network of experienced staff and collaborators [5][6] - The company is involved in projects related to molecular diagnostic systems and has managed product development teams across multiple countries [6] Product Development - Arete has reviewed engineering schematics and patent filings, incorporating FDA recommendations into their design plans [2] - A usability study with approximately ten participants will be conducted to assess the wearability and comfort of the GlucoGuard device, as directed by the FDA [2] - The project is expected to be completed within the next 7 to 10 days, with a development protocol devised under the guidance of Dr. Stephen Weber [3] GlucoGuard Overview - GlucoGuard is a patent-pending nocturnal glucose monitoring and delivery system aimed at preventing hypoglycemia in diabetic patients [8] - The system utilizes advanced engineering and AI to monitor glucose levels during sleep and administer glucose automatically when needed [9] Market Potential - The U.S. diabetes market is valued at $28 billion, indicating substantial growth potential for GlucoGuard [12] - The Continuous Glucose Monitoring (CGM) sector is valued at $6.8 billion, highlighting the demand for innovative glucose management solutions [12]